Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company focused on the needs of patients with severe bacterial and fungal infections, has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. In addition, Basilea has acquired the rights to a preclinical antifungal compound. Fosmanogepix is a potential first-in-class antifungal treatmen...